# RedHill Biopharma Ltd.: financial statements, quarterly

RDHL · Nasdaq · CIK 1553846 · [Healthcare](/sectors/healthcare.md)

Pages: [Overview](/companies/rdhl.md) · [Financials](/companies/rdhl/financials.md) · [Filings](/companies/rdhl/filings.md) · [Insiders](/companies/rdhl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rdhl/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2014-12-31) | period not labelled (2015-12-31) | period not labelled (2016-12-31) | FY2017 (2017-12-31) | FY2018 (2018-12-31) | FY2019 (2019-12-31) | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.9](/filings/0001558370-18-000892.md) | [21.5](/filings/0001558370-19-001037.md) | [53.8](/filings/0001558370-20-001994.md) | [16.5](/filings/0001558370-21-003168.md) | [29.0](/filings/0001558370-22-003806.md) | [29.0](/filings/0001558370-23-007149.md) | [29.3](/filings/0001558370-24-004806.md) | [29.5](/filings/0001558370-25-004648.md) | [20.0](/filings/0001558370-25-004648.md) | [5.6](/filings/0001558370-25-004648.md) | [4.6](/filings/0001558370-25-004648.md) |
| Current assets | $m | not reported | not reported | [67.8](/filings/0001558370-18-000892.md) | [51.7](/filings/0001558370-19-001037.md) | [56.8](/filings/0001558370-20-001994.md) | [53.2](/filings/0001558370-21-003168.md) | [70.5](/filings/0001558370-22-003806.md) | [89.2](/filings/0001558370-23-007149.md) | [85.9](/filings/0001558370-24-004806.md) | [16.1](/filings/0001558370-25-004648.md) | [11.9](/filings/0001558370-25-004648.md) |
| Total assets | $m | not reported | not reported | [74.2](/filings/0001558370-18-000892.md) | [57.3](/filings/0001558370-19-001037.md) | [62.4](/filings/0001558370-20-001994.md) | [74.1](/filings/0001558370-21-003168.md) | [180](/filings/0001558370-22-003806.md) | [181](/filings/0001558370-23-007149.md) | [159](/filings/0001558370-24-004806.md) | [23.0](/filings/0001558370-25-004648.md) | [18.0](/filings/0001558370-25-004648.md) |
| Current liabilities | $m | not reported | not reported | [5.4](/filings/0001558370-18-000892.md) | [11.8](/filings/0001558370-19-001037.md) | [10.4](/filings/0001558370-20-001994.md) | [10.6](/filings/0001558370-21-003168.md) | [73.2](/filings/0001558370-22-003806.md) | [81.5](/filings/0001558370-23-007149.md) | [197](/filings/0001558370-24-004806.md) | [20.0](/filings/0001558370-25-004648.md) | [22.2](/filings/0001558370-25-004648.md) |
| Total liabilities | $m | not reported | not reported | [11.5](/filings/0001558370-18-000892.md) | [12.3](/filings/0001558370-19-001037.md) | [11.2](/filings/0001558370-20-001994.md) | [14.1](/filings/0001558370-21-003168.md) | [166](/filings/0001558370-22-003806.md) | [172](/filings/0001558370-23-007149.md) | [207](/filings/0001558370-24-004806.md) | [21.0](/filings/0001558370-25-004648.md) | [22.7](/filings/0001558370-25-004648.md) |
| Shareholders' equity | $m | [25.0](/filings/0001558370-18-000892.md) | [60.1](/filings/0001558370-19-001037.md) | [62.7](/filings/0001558370-20-001994.md) | [45.1](/filings/0001558370-21-003168.md) | [51.2](/filings/0001558370-22-003806.md) | [60.0](/filings/0001558370-23-007149.md) | [13.9](/filings/0001558370-24-004806.md) | [8.9](/filings/0001558370-25-004648.md) | [(48.4)](/filings/0001558370-25-004648.md) | [2.1](/filings/0001558370-25-004648.md) | [(4.7)](/filings/0001558370-25-004648.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Total liabilities: ifrs-full:Liabilities
- Shareholders' equity: ifrs-full:Equity

Shares outstanding: 50,923,261,000 at 2025-12-31, from the cover of the [20-F filed 2026-04-27](/filings/0001104659-26-049055.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.